ORLANDO, Fla. — The topical Janus tyrosine kinase (JAK) 1/2 inhibitor ruxolitinib improved itching and nodules in patients with prurigo nodularis (PN) significantly better than a vehicle within a week after starting therapy, with improvements continuing out to 3 months, in a global phase 3 clinical trial...
.png)
55W 14th St Ste 101, Helena, MT, 59601 US
+1 (406) 319 1601
news.in.usa@olahost.top
Copyright © 2024 olasport. All Rights Reserved
